MSLN and hepatocellular carcinoma: Advances in solid tumor targeting continue to expand the repertoire of actionable antigens, including glypican-3 (GPC3) in hepatocellular carcinoma, Claudin18.2 in gastric cancer, mesothelin (MSLN), and B7-H3 across various malignancies.